Individualizing amikacin regimens : accurate method to achieve therapeutic concentrations
Amikacin's pharmacokinetics and dosage requirements were studied in 98 patients receiving treatment for gram-negative infections. A wide interpatient variation in the kinetic parameters of the drug occurred in all patients and in patients who had normal serum creatinine levels or normal creatin...
Gespeichert in:
| Veröffentlicht in: | Therapeutic drug monitoring 1991-11, Vol.13 (6), p.502-506 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 506 |
|---|---|
| container_issue | 6 |
| container_start_page | 502 |
| container_title | Therapeutic drug monitoring |
| container_volume | 13 |
| creator | ZASKE, D. E CIPOLLE, R. J ROTSCHAFER, J. C KOHLS, P. R STRATE, R. G |
| description | Amikacin's pharmacokinetics and dosage requirements were studied in 98 patients receiving treatment for gram-negative infections. A wide interpatient variation in the kinetic parameters of the drug occurred in all patients and in patients who had normal serum creatinine levels or normal creatinine clearance. The half-life ranged from 0.7 to 14.4 h in 74 patients who had normal serum creatinine levels and from 0.7 to 7.2 h in 37 patients who had normal creatinine clearance. The necessary daily dose to obtain therapeutic serum concentrations ranged from 1.25 to 57 mg/kg in patients with normal serum creatinine levels and from 10 to 57 mg/kg in patients with normal creatinine clearance. In four patients (4%), a significant change in baseline serum creatinine level (greater than 0.5 mg/dl) occurred during or after treatment, which may have been amikacin-associated toxicity. Overt ototoxicity occurred in one patient. The method of individualizing dosage regimens provided a clinically useful means of rapidly attaining therapeutic peak and trough serum concentrations. |
| doi_str_mv | 10.1097/00007691-199111000-00006 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00007691_199111000_00006</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1771647</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-8e54ec09128c6b2d65a3b94bde45e57eca1eeeeeae3c455d83ea20ea86f1301a3</originalsourceid><addsrcrecordid>eNpFkDtPwzAQxy0EKqXwEZA8sAZ88SMxG6p4VKrEAgNTdHGuraFxqjhBgk9PSku55XT_xw0_xjiIaxA2uxHDZMZCAtYCwHAlW8kcsTFoaRJprDpmYwFGJkpqc8rOYnwXAlQuxIiNIMvAqGzM3mah8p--6nHtv31Ycqz9BzofeEtLX1OI_Jajc32LHfGaulVT8a4ZpJWnT-LdilrcUN95x10THIVuSPomxHN2ssB1pIv9nrDXh_uX6VMyf36cTe_miUtz1SU5aUVOWEhzZ8q0MhplaVVZkdKkM3IItB0k6ZTWVS4JU0GYmwVIASgnLN_9dW0TY0uLYtP6GtuvAkSxhVX8wSoOsH4lM1Qvd9VNX9ZU_Rd3dAb_au9jdLhetBicj4eYhgGmsPIHD6hz8A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Individualizing amikacin regimens : accurate method to achieve therapeutic concentrations</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>ZASKE, D. E ; CIPOLLE, R. J ; ROTSCHAFER, J. C ; KOHLS, P. R ; STRATE, R. G</creator><creatorcontrib>ZASKE, D. E ; CIPOLLE, R. J ; ROTSCHAFER, J. C ; KOHLS, P. R ; STRATE, R. G</creatorcontrib><description>Amikacin's pharmacokinetics and dosage requirements were studied in 98 patients receiving treatment for gram-negative infections. A wide interpatient variation in the kinetic parameters of the drug occurred in all patients and in patients who had normal serum creatinine levels or normal creatinine clearance. The half-life ranged from 0.7 to 14.4 h in 74 patients who had normal serum creatinine levels and from 0.7 to 7.2 h in 37 patients who had normal creatinine clearance. The necessary daily dose to obtain therapeutic serum concentrations ranged from 1.25 to 57 mg/kg in patients with normal serum creatinine levels and from 10 to 57 mg/kg in patients with normal creatinine clearance. In four patients (4%), a significant change in baseline serum creatinine level (greater than 0.5 mg/dl) occurred during or after treatment, which may have been amikacin-associated toxicity. Overt ototoxicity occurred in one patient. The method of individualizing dosage regimens provided a clinically useful means of rapidly attaining therapeutic peak and trough serum concentrations.</description><identifier>ISSN: 0163-4356</identifier><identifier>EISSN: 1536-3694</identifier><identifier>DOI: 10.1097/00007691-199111000-00006</identifier><identifier>PMID: 1771647</identifier><identifier>CODEN: TDMODV</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aged ; Aging - metabolism ; Amikacin - administration & dosage ; Amikacin - adverse effects ; Amikacin - pharmacokinetics ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Genetic Variation - physiology ; Gram-Negative Bacterial Infections - drug therapy ; Gram-Negative Bacterial Infections - metabolism ; Humans ; Kidney - physiology ; Male ; Medical sciences ; Middle Aged ; Models, Biological ; Pharmacology. Drug treatments</subject><ispartof>Therapeutic drug monitoring, 1991-11, Vol.13 (6), p.502-506</ispartof><rights>1992 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5180009$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1771647$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ZASKE, D. E</creatorcontrib><creatorcontrib>CIPOLLE, R. J</creatorcontrib><creatorcontrib>ROTSCHAFER, J. C</creatorcontrib><creatorcontrib>KOHLS, P. R</creatorcontrib><creatorcontrib>STRATE, R. G</creatorcontrib><title>Individualizing amikacin regimens : accurate method to achieve therapeutic concentrations</title><title>Therapeutic drug monitoring</title><addtitle>Ther Drug Monit</addtitle><description>Amikacin's pharmacokinetics and dosage requirements were studied in 98 patients receiving treatment for gram-negative infections. A wide interpatient variation in the kinetic parameters of the drug occurred in all patients and in patients who had normal serum creatinine levels or normal creatinine clearance. The half-life ranged from 0.7 to 14.4 h in 74 patients who had normal serum creatinine levels and from 0.7 to 7.2 h in 37 patients who had normal creatinine clearance. The necessary daily dose to obtain therapeutic serum concentrations ranged from 1.25 to 57 mg/kg in patients with normal serum creatinine levels and from 10 to 57 mg/kg in patients with normal creatinine clearance. In four patients (4%), a significant change in baseline serum creatinine level (greater than 0.5 mg/dl) occurred during or after treatment, which may have been amikacin-associated toxicity. Overt ototoxicity occurred in one patient. The method of individualizing dosage regimens provided a clinically useful means of rapidly attaining therapeutic peak and trough serum concentrations.</description><subject>Adult</subject><subject>Aged</subject><subject>Aging - metabolism</subject><subject>Amikacin - administration & dosage</subject><subject>Amikacin - adverse effects</subject><subject>Amikacin - pharmacokinetics</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Genetic Variation - physiology</subject><subject>Gram-Negative Bacterial Infections - drug therapy</subject><subject>Gram-Negative Bacterial Infections - metabolism</subject><subject>Humans</subject><subject>Kidney - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><issn>0163-4356</issn><issn>1536-3694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkDtPwzAQxy0EKqXwEZA8sAZ88SMxG6p4VKrEAgNTdHGuraFxqjhBgk9PSku55XT_xw0_xjiIaxA2uxHDZMZCAtYCwHAlW8kcsTFoaRJprDpmYwFGJkpqc8rOYnwXAlQuxIiNIMvAqGzM3mah8p--6nHtv31Ycqz9BzofeEtLX1OI_Jajc32LHfGaulVT8a4ZpJWnT-LdilrcUN95x10THIVuSPomxHN2ssB1pIv9nrDXh_uX6VMyf36cTe_miUtz1SU5aUVOWEhzZ8q0MhplaVVZkdKkM3IItB0k6ZTWVS4JU0GYmwVIASgnLN_9dW0TY0uLYtP6GtuvAkSxhVX8wSoOsH4lM1Qvd9VNX9ZU_Rd3dAb_au9jdLhetBicj4eYhgGmsPIHD6hz8A</recordid><startdate>19911101</startdate><enddate>19911101</enddate><creator>ZASKE, D. E</creator><creator>CIPOLLE, R. J</creator><creator>ROTSCHAFER, J. C</creator><creator>KOHLS, P. R</creator><creator>STRATE, R. G</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19911101</creationdate><title>Individualizing amikacin regimens : accurate method to achieve therapeutic concentrations</title><author>ZASKE, D. E ; CIPOLLE, R. J ; ROTSCHAFER, J. C ; KOHLS, P. R ; STRATE, R. G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-8e54ec09128c6b2d65a3b94bde45e57eca1eeeeeae3c455d83ea20ea86f1301a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aging - metabolism</topic><topic>Amikacin - administration & dosage</topic><topic>Amikacin - adverse effects</topic><topic>Amikacin - pharmacokinetics</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Genetic Variation - physiology</topic><topic>Gram-Negative Bacterial Infections - drug therapy</topic><topic>Gram-Negative Bacterial Infections - metabolism</topic><topic>Humans</topic><topic>Kidney - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ZASKE, D. E</creatorcontrib><creatorcontrib>CIPOLLE, R. J</creatorcontrib><creatorcontrib>ROTSCHAFER, J. C</creatorcontrib><creatorcontrib>KOHLS, P. R</creatorcontrib><creatorcontrib>STRATE, R. G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Therapeutic drug monitoring</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ZASKE, D. E</au><au>CIPOLLE, R. J</au><au>ROTSCHAFER, J. C</au><au>KOHLS, P. R</au><au>STRATE, R. G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Individualizing amikacin regimens : accurate method to achieve therapeutic concentrations</atitle><jtitle>Therapeutic drug monitoring</jtitle><addtitle>Ther Drug Monit</addtitle><date>1991-11-01</date><risdate>1991</risdate><volume>13</volume><issue>6</issue><spage>502</spage><epage>506</epage><pages>502-506</pages><issn>0163-4356</issn><eissn>1536-3694</eissn><coden>TDMODV</coden><abstract>Amikacin's pharmacokinetics and dosage requirements were studied in 98 patients receiving treatment for gram-negative infections. A wide interpatient variation in the kinetic parameters of the drug occurred in all patients and in patients who had normal serum creatinine levels or normal creatinine clearance. The half-life ranged from 0.7 to 14.4 h in 74 patients who had normal serum creatinine levels and from 0.7 to 7.2 h in 37 patients who had normal creatinine clearance. The necessary daily dose to obtain therapeutic serum concentrations ranged from 1.25 to 57 mg/kg in patients with normal serum creatinine levels and from 10 to 57 mg/kg in patients with normal creatinine clearance. In four patients (4%), a significant change in baseline serum creatinine level (greater than 0.5 mg/dl) occurred during or after treatment, which may have been amikacin-associated toxicity. Overt ototoxicity occurred in one patient. The method of individualizing dosage regimens provided a clinically useful means of rapidly attaining therapeutic peak and trough serum concentrations.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>1771647</pmid><doi>10.1097/00007691-199111000-00006</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-4356 |
| ispartof | Therapeutic drug monitoring, 1991-11, Vol.13 (6), p.502-506 |
| issn | 0163-4356 1536-3694 |
| language | eng |
| recordid | cdi_crossref_primary_10_1097_00007691_199111000_00006 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Aging - metabolism Amikacin - administration & dosage Amikacin - adverse effects Amikacin - pharmacokinetics Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Dose-Response Relationship, Drug Drug Administration Schedule Female Genetic Variation - physiology Gram-Negative Bacterial Infections - drug therapy Gram-Negative Bacterial Infections - metabolism Humans Kidney - physiology Male Medical sciences Middle Aged Models, Biological Pharmacology. Drug treatments |
| title | Individualizing amikacin regimens : accurate method to achieve therapeutic concentrations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A12%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Individualizing%20amikacin%20regimens%20:%20accurate%20method%20to%20achieve%20therapeutic%20concentrations&rft.jtitle=Therapeutic%20drug%20monitoring&rft.au=ZASKE,%20D.%20E&rft.date=1991-11-01&rft.volume=13&rft.issue=6&rft.spage=502&rft.epage=506&rft.pages=502-506&rft.issn=0163-4356&rft.eissn=1536-3694&rft.coden=TDMODV&rft_id=info:doi/10.1097/00007691-199111000-00006&rft_dat=%3Cpubmed_cross%3E1771647%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/1771647&rfr_iscdi=true |